Raymond James initiates Quince Therapeutics stock coverage with outperform rating
Raymond James initiated coverage on Quince Therapeutics (NASDAQ:QNCX) with an outperform rating and $72 price target, citing its LAM-001 drug for pulmonary diseases. The stock trades near its $30.41 fair value, with a $29.86M market cap and no expected profitability this year. Other analysts also gave positive ratings and targets. The company plans a stockholder meeting to vote on issuing shares, potentially changing control. LAM-001 remains a key focus.
How this was made
The 30-second read
Why it matters
The new coverage and price target provide a fresh data point for investors, potentially prompting short‑term buying pressure.
Market read
Analyst initiation on a micro‑cap biotech creates a short‑term trading opportunity, especially given the large upside implied by the target.
What to watch
Potential dilution from the upcoming special meeting and conversion of preferred shares could offset upside.
Background
Quince Therapeutics recently completed a reverse merger with Orphai Therapeutics and is developing LAM-001, an inhaled rapamycin formulation for rare pulmonary diseases.
Ticker impact
Raymond James initiated coverage on Quince Therapeutics with an Outperform rating and a $72 price target, the first such analyst report for the micro‑cap biotech.
likely upward pressure as the market absorbs the new Outperform rating and $72 target.
Coverage initiation is a fresh catalyst for a low‑float stock; the sizable target versus current price suggests upside potential.
Market effects
May lift sentiment in the niche pulmonary‑disease biotech segment.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The $72 target may be overly optimistic given the company's cash burn and lack of near‑term profitability.
Key entities
- companyQuince Therapeutics Inc.
Biotech firm developing LAM-001 for pulmonary hypertension.
- analyst_firmRaymond James
Initiated coverage with Outperform rating and $72 target.
